TMPRSS3 Human shRNA Plasmid Kit (Locus ID 64699)

CAT#: TR300925

TMPRSS3 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector

Specifications

Product Data

• Locus ID: 64699
• Synonyms: DFNB8; DFNB10; ECHOS1; TADG12
• Vector: pRS
• Format: Retroviral plasmids
• Kit Components: TMPRSS3 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 64699). 5µg purified plasmid DNA per construct
  Non-effective 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
• RefSeq: NM_001256317, NM_024022, NM_032401, NM_032404, NM_032405, NR_027348, NR_046020, BC074846, BC074847
• Summary: This gene encodes a protein that belongs to the serine protease family. The encoded protein contains a serine protease domain, a transmembrane domain, an LDL receptor-like domain, and a scavenger receptor cysteine-rich domain. Serine proteases are known to be involved in a variety of biological processes, whose malfunction often leads to human diseases and disorders. This gene was identified by its association with both congenital and childhood onset autosomal recessive deafness. This gene is expressed in fetal cochlea and many other tissues, and is thought to be involved in the development and maintenance of the inner ear or the contents of the perilymph and endolymph. This gene was also identified as a tumor-associated gene that is overexpressed in ovarian tumors. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jan 2012]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).